Adaptive Biotechnologies ... (ADPT)
Adaptive Biotechnologies Statistics
Share Statistics
Adaptive Biotechnologies has 148.58M shares outstanding. The number of shares has increased by 1.71% in one year.
| Shares Outstanding | 148.58M |
| Shares Change (YoY) | 1.71% |
| Shares Change (QoQ) | 0.07% |
| Owned by Institutions (%) | 97.08% |
| Shares Floating | 141.74M |
| Failed to Deliver (FTD) Shares | 1.99K |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 8.66M, so 5.87% of the outstanding shares have been sold short.
| Short Interest | 8.66M |
| Short % of Shares Out | 5.87% |
| Short % of Float | 6.06% |
| Short Ratio (days to cover) | 6.51 |
Valuation Ratios
The PE ratio is -5.53 and the forward PE ratio is -9.1. Adaptive Biotechnologies's PEG ratio is 0.18.
| PE Ratio | -5.53 |
| Forward PE | -9.1 |
| PS Ratio | 4.93 |
| Forward PS | 3.4 |
| PB Ratio | 4.35 |
| P/FCF Ratio | -8.93 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Adaptive Biotechnologies Corporation has an Enterprise Value (EV) of 871.85M.
| EV / Earnings | -5.47 |
| EV / Sales | 4.87 |
| EV / EBITDA | -6.77 |
| EV / EBIT | -5.36 |
| EV / FCF | -8.82 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.44.
| Current Ratio | 2.89 |
| Quick Ratio | 2.81 |
| Debt / Equity | 0.44 |
| Total Debt / Capitalization | 30.6 |
| Cash Flow / Debt | -1.07 |
| Interest Coverage | -14.04 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -55.69%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -55.69% |
| Revenue Per Employee | $289,106.62 |
| Profits Per Employee | $-257,660.74 |
| Employee Count | 619 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 8.54 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 155.76% in the last 52 weeks. The beta is 1.53, so Adaptive Biotechnologies's price volatility has been higher than the market average.
| Beta | 1.53 |
| 52-Week Price Change | 155.76% |
| 50-Day Moving Average | 7.86 |
| 200-Day Moving Average | 5.62 |
| Relative Strength Index (RSI) | 55.19 |
| Average Volume (20 Days) | 1.74M |
Income Statement
In the last 12 months, Adaptive Biotechnologies had revenue of 178.96M and earned -159.49M in profits. Earnings per share was -1.08.
| Revenue | 178.96M |
| Gross Profit | 106.88M |
| Operating Income | -162.55M |
| Net Income | -159.49M |
| EBITDA | -128.76M |
| EBIT | -162.55M |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has 47.92M in cash and 89.39M in debt, giving a net cash position of -41.47M.
| Cash & Cash Equivalents | 47.92M |
| Total Debt | 89.39M |
| Net Cash | -41.47M |
| Retained Earnings | -1.3B |
| Total Assets | 539.38M |
| Working Capital | 185.7M |
Cash Flow
In the last 12 months, operating cash flow was -95.21M and capital expenditures -3.66M, giving a free cash flow of -98.88M.
| Operating Cash Flow | -95.21M |
| Capital Expenditures | -3.66M |
| Free Cash Flow | -98.88M |
| FCF Per Share | -0.67 |
Margins
Gross margin is 59.72%, with operating and profit margins of -90.83% and -89.12%.
| Gross Margin | 59.72% |
| Operating Margin | -90.83% |
| Pretax Margin | -89.12% |
| Profit Margin | -89.12% |
| EBITDA Margin | -71.95% |
| EBIT Margin | -90.83% |
| FCF Margin | -55.25% |
Dividends & Yields
ADPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.15% |
| FCF Yield | -8.11% |
Analyst Forecast
The average price target for ADPT is $9, which is 9.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 9.6% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -1.25 |
| Piotroski F-Score | 4 |